
David Llobet-Navas

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7871888/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	<i>ARID1A</i> â€deficient cells require HDAC6 for progression of endometrial carcinoma. Molecular Oncology, 2022, 16, 2235-2259.	2.1	9
2	A microRNA Cluster Controls Fat Cell Differentiation and Adipose Tissue Expansion By Regulating SNCG. Advanced Science, 2022, 9, 2104759.	5.6	9
3	Metabolomic Analysis Points to Bioactive Lipid Species and Acireductone Dioxygenase 1 (ADI1) as Potential Therapeutic Targets in Poor Prognosis Endometrial Cancer. Cancers, 2022, 14, 2842.	1.7	6
4	A compound directed against S6K1 hampers fat mass expansion and mitigates diet-induced hepatosteatosis. JCI Insight, 2022, 7, .	2.3	2
5	Autophagy in the physiological endometrium and cancer. Autophagy, 2021, 17, 1077-1095.	4.3	100
6	Neuronal Differentiation-Related Epigenetic Regulator ZRF1 Has Independent Prognostic Value in Neuroblastoma but Is Functionally Dispensable In Vitro. Cancers, 2021, 13, 4845.	1.7	0
7	Guidelines for the use and interpretation of assays for monitoring autophagy (4th) Tj ETQq1 1 0.784314 rgBT /O	verlock 10 4.3	Tf 50 502 T 1,430
8	The oral KIF11 inhibitor 4SCâ€205 exhibits antitumor activity and potentiates standard and targeted therapies in primary and metastatic neuroblastoma models. Clinical and Translational Medicine, 2021, 11, e533.	1.7	7
9	miRâ€424/503 modulates Wnt/βâ€catenin signaling in the mammary epithelium by targeting LRP6. EMBO Reports, 2021, 22, e53201.	2.0	2
10	The number of titrated microRNA species dictates ceRNA regulation. Nucleic Acids Research, 2018, 46, 4354-4369.	6.5	32
11	Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy, 2017, 13, 608-624.	4.3	65
12	miR-424(322)/503 is a breast cancer tumor suppressor whose loss promotes resistance to chemotherapy. Genes and Development, 2017, 31, 553-566.	2.7	87
13	Endometrial Carcinoma: Specific Targeted Pathways. Advances in Experimental Medicine and Biology, 2017, 943, 149-207.	0.8	53
14	A Smad3-PTEN regulatory loop controls proliferation and apoptotic responses to TGF-Î ² in mouse endometrium. Cell Death and Differentiation, 2017, 24, 1443-1458.	5.0	24
15	Overexpression of JARID1B promotes differentiation via SHIP1/AKT signaling in human hypopharyngeal squamous cell carcinoma. Cell Death and Disease, 2016, 7, e2358-e2358.	2.7	20
16	HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. Breast Cancer Research, 2015, 17, 149.	2.2	42
17	Inhibition of the autocrine IL-6–JAK2–STAT3–calprotectin axis as targeted therapy for HR ^{â^'} /HER2 ⁺ breast cancers. Genes and Development, 2015, 29, 1631-1648.	2.7	94
18	Cupid: simultaneous reconstruction of microRNA-target and ceRNA networks. Genome Research, 2015, 25, 257-267.	2.4	94

DAVID LLOBET-NAVAS

#	Article	IF	CITATIONS
19	The MicroRNA 424/503 Cluster Reduces CDC25A Expression during Cell Cycle Arrest Imposed by Transforming Growth Factor β in Mammary Epithelial Cells. Molecular and Cellular Biology, 2014, 34, 4216-4231.	1.1	39
20	Integration of Genomic Data Enables Selective Discovery of Breast Cancer Drivers. Cell, 2014, 159, 1461-1475.	13.5	77
21	The <i>miR-424(322)/503</i> cluster orchestrates remodeling of the epithelium in the involuting mammary gland. Genes and Development, 2014, 28, 765-782.	2.7	66
22	A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia. Nature Medicine, 2014, 20, 1130-1137.	15.2	349
23	ÂÂÂÂÂÂN-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL. Blood, 2014, 124, 487-487.	0.6	0
24	ERα-mediated repression of pro-inflammatory cytokine expression by glucocorticoids reveals a critical role for TNFα and IL1α in lumen formation and maintenance Journal of Cell Science, 2012, 125, 1929-44.	1.2	11
25	TNFR-Associated Factor 2 Deficiency in B Lymphocytes Predisposes to Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma in Mice. Journal of Immunology, 2012, 189, 1053-1061.	0.4	18
26	Epithelial to mesenchymal transition in early stage endometrioid endometrial carcinoma. Human Pathology, 2012, 43, 632-643.	1.1	75
27	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. American Journal of Pathology, 2011, 178, 1529-1543.	1.9	30
28	An Extensive MicroRNA-Mediated Network of RNA-RNA Interactions Regulates Established Oncogenic Pathways in Glioblastoma. Cell, 2011, 147, 370-381.	13.5	671
29	A Novel Three-Dimensional Culture System of Polarized Epithelial Cells to Study Endometrial Carcinogenesis. American Journal of Pathology, 2010, 176, 2722-2731.	1.9	46
30	CK2β Is Expressed in Endometrial Carcinoma and Has a Role in Apoptosis Resistance and Cell Proliferation. American Journal of Pathology, 2009, 174, 287-296.	1.9	42
31	Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood, 2009, 113, 4595-4603.	0.6	48
32	CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene, 2008, 27, 2513-2524.	2.6	48
33	Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. British Journal of Dermatology, 2008, 158, 496-504.	1.4	41
34	Nuclear factor–îºB activation is associated with somatic and germ line RET mutations in medullary thyroid carcinoma. Human Pathology, 2008, 39, 994-1001.	1.1	25
35	Targeted therapies in gynecologic cancers and melanoma. Seminars in Diagnostic Pathology, 2008, 25, 262-273.	1.0	8
36	Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anti-Cancer Drugs, 2008, 19, 115-124.	0.7	51

#	Article	IF	CITATIONS
37	PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterationsâ [~] †. Human Pathology, 2006, 37, 1465-1472.	1.1	134
38	Proteasome Inhibitors Induce Death but Activate NF-κB on Endometrial Carcinoma Cell Lines and Primary Culture Explants. Journal of Biological Chemistry, 2006, 281, 22118-22130.	1.6	94
39	Survivin Expression in Endometrial Carcinoma:. International Journal of Gynecological Pathology, 2005, 24, 247-253.	0.9	62
40	FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Laboratory Investigation, 2005, 85, 885-894.	1.7	59
41	Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Modern Pathology, 2005, 18, 719-727.	2.9	110
42	NF-kB in development and progression of human cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2005, 446, 475-482.	1.4	926
43	Abnormalities in the NF-ήB family and related proteins in endometrial carcinoma. Journal of Pathology, 2004, 204, 569-577.	2.1	101